CETSA® by Pelago can be adapted for different applications to support any stage of the drug discovery process from low-throughput confirmation and high-throughput discovery to proteome-wide exploration – these methods rely on the same principle: measurements of the ‘thermal shift…
Pelago Bioscience AB expands to new facility After several years of continued growth in our current facilities Pelago Bioscience now really expands. The new building is located at Campus Solna, a rapidly developing Life Science cluster located in central…
Confirmation of target engagement in relevant physiological environment ensures successful drug discovery and the right project prioritization. By applying CETSA®, you can make better and more informed decisions at earlier stages in your drug discovery projects. Welcome to learn from…
Time to celebrate – For the third year in a row, Pelago has been awarded the prestigious DI Gasell prize by the Swedish daily business newspaper Dagens Industri. This prize recognizes the fastest growing Swedish companies, with less than 1…
We have the pleasure to announce that the French Ministry for Higher Education and Research has recognised Pelago Bioscience AB as an approved research and development service provider. This allows companies, subject to the French General Tax Code, to take…
Don’t miss this new interesting CETSA® paper published in Nature Protocols. https://www.nature.com/articles/s41596-020-0310-z Are you sure? Is you target compound really theraputic? Speak to our experts Learn how CETSA® can enable your project by talking to one of our Drug Discovery…
